Use of DPP-4 Inhibitors May Increase Risk of Developing Bullous Pemphigoid in Diabetic Patients

Dipeptidyl-Peptidase 4 Inhibitors (DPP-4), belong to a class of anti-hyperglycemic agents indicated for improving glycemic control in patients with type-2 diabetes. As their use has increased, so has the number of cases of Bullous Pemphigoid (BP), a chronic skin disorder characterized by blisters, hives and itching. A recent study used a case-control method to answer …